# A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia

> **NCT00515034** · PHASE2 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 146 (actual)

## Conditions studied

- Pneumonia, Ventilator-Associated
- Pneumonia, Bacterial
- Pneumonia
- Abdominal Abscess
- Bacterial Infections

## Interventions

- **DRUG:** Imipenem/cilastatin
- **DRUG:** Imipenem/cilastatin
- **DRUG:** Doripenem
- **DRUG:** Doripenem

## Key facts

- **NCT ID:** NCT00515034
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00515034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00515034, "A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00515034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*